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[57] ABSTRACT 
Compositions containing PBN, or active derivatives 
thereof, in a suitable pharmaceutical carrier for adminis 
tration to a patient, are disclosed for treating or prevent 
ing gastric ulceration caused by ingestion of non-steroi 
dal anti-in?ammatories. Based on animal studies, the 
dosage is in the range of 3 to 300 mg/kg and is adminis 
tered prior to, simultaneously, or shortly after ingestion 
of the NSAID compound(s). In the preferred embodi 
ment, the range is between 10 and 30 mg/kg, depending 
on the dosage unit required to protect the mucosa. The 
preferred method of administration is orally, alone or in 
combination with the non-steroidal anti-in?ammatory. 
It is believed that the PBN is also useful alone for treat 
ment or prevention of ulcers, aspects of diarrhea, gastri 
tis, esophagitis, ileitis, and as an analgesic. 
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PHENYLBUTYL NITRONE COMPOSITIONS AND 
METHODS FOR PREVENTION OF GASTRIC 
ULCERATION 
The United States Government has certain rights in 
this invention by virtue of grants from the National 
Institutes of Health. 
BACKGROUND OF THE INVENTION 
This is a continuation-in-part of US. Ser. No. 
07/422,651 entitled “Phenyl Butyl Nitrone Composi 
tions for Treatment of Oxidative Tissue Damage” ?led 
Oct. 17, 1989 by John M. Carney and Robert A. Floyd. 
This is generally in the area of compositions and 
methods for use thereof for the treatment and preven 
tion of gastrointestinal ulceration resulting from the use 
of nonsteroidal anti-inflammatory compounds, wherein 
the active compounds are phenyl butylnitrone (PBN) or 
derivatives thereof. 
Gastric ulceration is among the most important of 
adverse reactions from aspirin and nonsteroidal anti-in 
?ammatory drugs (NSAIDS). The currently accepted 
explanation for NSAID-induced gastric ulceration is 
that NSAIDS inhibit synthesis of cytoprotective prosta 
glandins, as reviewed by Whittle, B. R., and J. R. Vane. 
Arch. Toxicol. Suppl 7:315-322 (1984). This hypothesis 
is supported by the demonstration that exogenous pros 
taglandins protect from NSAID-relatecl gastric ulcers 
by Graham, D. Y., et a1. Lancet 2:1277-1280 (1988), but 
challenged by recent studies showing that NSAIDS can 
inhibit gastric prostaglandin production without caus 
ing ulceration, as reported by Rainsford, K. D., et al. 
Scand. J. Gastroenterol. 19 (Suppl 101):_35-68 (1984); 
Ligumsky, M., et a1. Gastroenterology 84:756-761 
(1985); and Rainsford, K. D., “Relationship between 
drug absorption, inhibition of cyclo-oxygenase and 
lipoxygenase pathways and the development of gastric 
mucosal damage of non-steroidal anti-in?ammatory 
drugs in rats and pigs”. In Advances in Prostaglandins, 
Leukotrienes and Lipoxins. M. J. Bailey, editor. Plenum 
Press, New York, 639-653 (1985).. Thus, the cause of 
NSAID-induced gastric ulceration remains controver 
sial, as reviewed by Rainsford, K. D. Toxicologic 
Pathol. 16:251-259 (1988). 
Free radicals have been postulated to be mediators of 
tissue injury including that brought on by ischemical 
reperfusion damage. Important production sites of the 
oxygen free radicals Superoxide (02-) and hydroxyl 
(OH) radicals are the mitochondrial respiratory chain 
and the reaction sequences catalyzed by cyclooxyge 
nase and lipoxygenase. However, radicals are also 
formed during autoxidation of many compounds (e.g., 
catecholamines). Ischemic events in tissue causes a 
spurt of free-radical formation. This may be due to 
oxidation of polyenoic free fatty acids, release and reup 
take of catecholamines, and oxidation of xanthine and 
hypoxanthine by xanthine oxidase. Although all these 
events occur during recirculation, when the 0; supply 
is restored after ischemia, they represent metabolic 
cascades triggered by agonistreceptor interactions, en 
ergy failure, and/or calcium in?ux during the insult. 
Although free radical formation is a likely cause of 
ischemic damage, it has been dif?cult to directly dem 
onstrate that such formation occurs and/or that it is 
suf?ciently pronounced to overwhelm the antioxidative 
defense of the tissue, Curran, et al., Mol. Cell. Biol. 5, 
167-172 (1985). In recent years, however, evidence has 
20 
25 
40 
65 
2 
been obtained that ischemia may cause conjugated di 
enes and malondialdehyde to accumulate in the tissue. 
Even so, it remains to be conclusively shown that free 
radical damage to unsaturated acyl chains in phospho 
lipids, to protein, or to nucleic acids constitutes an im 
portant role in the ischemic necrosis. At present, the 
evidence is relatively strong for an involvement of free 
radical mechanisms in vascular injury, and in damage 
affecting nerve and glial cells. 
Although no drugs are currently approved for clini 
cal use in treating tissue damage due to ischemia, sev 
eral compounds have been proposed as potentially 
being effective. Mannitol, an oxygen scavenger, has 
been added to reperfusion media to limit damage to 
organs for transplantation. Superoxide dismutase 
(SOD) has been suggested as a means for limiting in 
vivo oxidative damage. The most promising com 
pounds that interfere with peroxidation generation are 
the lazaroides, modi?ed prednisones, described by J. M. 
McCall, Acta Anesthesia Belgica, First Antwerp Int. 
Trauma Symp., which have been reported to be effica 
cious if given during or after ischemia. White and Aust 
and co-workers, Adv. Free Radical Biol. Med.l,l-l7 
(1985), and Babbs, Resuscitation 13, 165-173 (1986), 
have demonstrated that iron chelators protect animals 
from ischemia/reperfusion injury. 
It is therefore an object of the present invention to 
provide composition and methods for use thereof which 
are useful in preventing or treating gastric ulcers result 
ing from the use of non-steroidal anti-inflammatory 
compounds. 
It is a further object of the present invention to pro 
vide compositions and methods for use thereof which 
are useful in preventing or treating pain and fever in 
vivo resulting from infection and in?ammation. 
SUMMARY OF THE INVENTION 
Compositions containing PBN, or active derivatives 
thereof, in a suitable pharmaceutical carrier for adminis 
tration to a patient, are disclosed for treating or prevent 
ing gastric ulceration caused by ingestion of non-steroi 
dal anti-inflammatories. The compositions have the 
following general formula: 
H 0' 
\ / 
C=N + 
/ \ 
X Y 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, . 
ll 
Z—C-, or Z; or -CH=N 
Y 
and n is a whole integer from 1 to 5; or 
5,036,097 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
or Z; and 
‘Z is a C1 to C5 straight or branched alkyl group. 
Based on animal studies, the dosage is in the range of 
3 to 300 mg/kg and is administered prior to, simulta 
neously, or shortly after ingestion of the NSAID com 
pound(s). In the preferred embodiment, the range is 
between 10 and 30 mg/kg, depending on the dosage 
unit required to protect the mucosa. The preferred 
method of administration is orally, alone or in combina 
tion with the non-steroidal anti-in?ammatory. It is be 
lieved that the PBN is also useful alone for treatment or 
prevention of ulcers, aspects of diarrhea, gastritis, 
esophagitis, ileitis, and possibly pain and fever in a man 
ner analogous to analgesics such as aspirin and acetami 
nophen. 
BRIEF DESCRIPTION OF THE DRAWINGS 
FIG. 1 is a comparison of the stomach from a pirox 
icam treated 'rat (right) to the stomach from a vehicle 
control treated rat (left). Piroxicam at 23 mg/kg caused 
prominent ulceration along the ridges of gastric rugae. 
FIG. 2 is a graph of % control ulceration from pirox 
icam versus the % ulceration in the presence of free 
radical scavengers. The sulthydryl scavenger dimethyl 
thiourea (DMTU, 500 mg/kg i.p.) was given 24 hours 
and 1 hour before piroxicam. The sulfhydryl scavenger 
N-acetylcysteine (300 mg/kg), the hydroquinone acet 
aminophen (400 mg/kg) and the spin-trap phenylbutyl 
nitrone (PBN, 30 mg/kg) were given orally 1 hour 
before and along with piroxicam. The antioxidant butyl 
ated hydroxytoluene (BHT, 25 mg/kg/day i.p. in corn 
oil) was given for three days before and again 1 hour 
before piroxicam. The % control ulceration is deter 
mined by averaging the ratios of cm2 ulceration in con 
trol stomachs from rats given piroxicam alone, and 
multiplying><100. +P< 0.01 compared to piroxicam 
alone. 
DETAILED DESCRIPTION OF THE 
INVENTION 
Gastric parietal cells have abundant mitochondria to 
. generate the energy required for hydrogen ion secre 
tion. Salicylate and NSAIDS have long been recog 
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nized as uncouplers of mitochondrial oxidative phos 
phorylation, and aspirin decreases mucosal adenosine 
triphosphate (ATP) and phosphocreatine (PC) in iso 
lated perfused gastric mucosa. Thus, aspirin and 
. NSAIDS might be expected to produce changes in the 
energy state of gastric mucosa similar to those caused 
by ischemia, when ATP is depleted and then degraded 
to hypoxanthine, as discussed by McCord, J. M. N. 
Engl. J, Med. 312:l58—l63 (1985). Xanthine oxidase 
mediated ischemia-reperfusion injury of the stomach 
has recently been reported as a cause of stress ulceration 
in hemorrhagic shock, as reported by Itoh, M., and P. 
H. Guth. Gastroenterology 88:1162-1167 (1985); Perry, 
M. A., et a1. Gastroenterology 90:362-367 (1986); and 
Smith, S. M., Gastroenterology 92:950—-956 (1987). If 
aspirin and NSAIDS impair mitochondrial energy me 
tabolism, the subsequent breakdown of high energy 
purines to xanthine might also stimulate xanthine oxi 
dase-mediated oxidant injury in gastric mucosa, result 
ing in ulceration. 
It has now been discovered that, further to the meth 
ods using PBN for the treatment and prevention of 
ischemic damage, including by decreasing or prevent 
ing ATP depletion, described and claimed in US. Ser. 
No. 07/422,651 filed Oct. 17, I989, PBN, and deriva 
tives thereof having spin-trapping activity, are useful in 
preventing or treating gastric ulceration resulting from 
ingestion of non-steroidal anti-inflammatories. As used 
herein, a free radical scavenger or spin-trap reagent is a ‘ 
molecule that will form a stable complex with a free 
radical. A free radical carbon trap is a molecule in 
which the free radical is localized on a carbon atom or 
a nitrogen atom. As a result of this chemical bond for 
mation, the free radical is no longer damaging to the 
cell. 
a-phenyl t-butyl nitrone (PBN), and derivatives 
thereof, in a pharmaceutical ‘vehicle suitable for admin 
istration to a patient, preferably by oral administration, 
are useful in preventing or reversing gastric ulceration 
caused by the use of ‘non-steroidal anti-in?ammatories 
(NSAID). PBN has a number of advantages in the treat 
ment of gastric ulceration, especially its complete lack 
of a measurable effect on normal or uninjured cells. 
PBN is the preferred active compound at this time, 
although a number of derivatives are also useful, includ 
ing hydroxy derivatives, especially 2-, 3-or 4-hydroxy 
PBN and mono-, di- and trihydroxy tert-butyl nitrone; 
esters, especially esters which release 2-, 3, or 4-hydrox 
yphenyl t-butyl nitrone such as the acetoxy derivative, 
2-, 3-, or 4-carboxyphenyl t-butyl nitrone, such as the 
ethyl derivative, or phenyl hydroxybutyl nitrone, such 
as the acetoxy derivative; alkoxyl derivatives, especially 
alkoxyl derivatives which release 2-, or 4-hydroxyphe 
nyl t-butyl nitrone, such as the methyl derivative; and 
acetamide derivatives, especially acetarnide derivatives 
which release 2-, or 4 aminophenyl t-butyl nitrone, such 
as the acetyl derivative; diphenyl nitrone (PPN) and the 
analogous diphenyl nitrone derivatives. As used herein, 
“PBN” refers to both a-phenyl t-butyl nitrone and de 
rivatives thereof, unless otherwise stated. The active 
agent in the compositions is N-tert-Butyl-a-phenylni 
trone (PBN) or derivatives thereof that are spin trap 
reagents and, in addition to chemical binding of free 
radicals, may also act to prevent ATP depletion of cells. 
The general formula for PBN and useful derivatives 
thereof is: 
5,03 6,097 
5 
H O‘ 
\ / 
C=N + 
/ \ 
X Y 
wherein: 
X is phenyl or 
(0R)n 
wherein R is H, 
and n is a whole integer from 1 to 5; or 
Y is tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group. 
The compositions can also contain other active 
agents, such as buffering agents such as antacids or inert 
carriers such as lactose. Examples of commonly used 
NSAIDs include aspirin, acetaminophen, ibuprofen, 
piroxicam, naphroxen, flufenamic and methanamic acid 
and related nonsteroidal antiinflammatory compounds. 
Examples demonstrate the utility of the compositions 
in preventing or treating ulceration resulting from in 
gestion of NSAIDs. Exemplary dosages of PBN ranged 
from 3 to 300 mg/kg of body weight in animals. The 
effective range of PBN in humans and other mammals is 
expected to be between approximately _ l0 and 300 
mg/kg, preferably between 10 and 30 mg/kg body 
weight. The compositions can be effectively adminis 
tered prior to, during or shortly after ingestion of 
NSAIDs, and prevent or decrease the extent of cellular 
damage. 
Since the trapping of endogenous free radicals is 
speci?c for only ‘those cells that have been exposed to 
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the conditions that result in the production of free radi 
cals, the traps have little or no effect on normal cells. 
The bene?cial effects occur only in injured cells, and do 
not require the presence of speci?c receptors, speci?c 
enzymes, and/or speci?c cell types. 
The PBN is preferably administered systemically, 
most preferably orally, since this is the most rapid and 
ef?cient means for delivering the active compound to 
the site of free radical generation. The PBN may be 
administered at once, or may be divided into a number 
of smaller doses to be administered at varying intervals 
of time. Other methods of administration can also be 
used, including subcutaneous, intravenous, and intra-_ 
peritoneal administration. The pharmaceutical compo 
sitions should provide a dosage of PBN relative to the 
dosage of NSAID sufficient to protect the mucosa from 
the effect of the NSAID. The concentration of active 
compound in the drug composition will depend on 
absorption, inactivation, and excretion rates of the drug , 
as well as other factors known to those skilled in the art. 
The compositions are administered prior to, at the same 
time as, or shortly after ingestion of the non-steroidal 
anti-in?ammatories. The effective dosage may also be 
determined based on that amount required to prevent or 
reverse predisposition of the cells to damage resulting 
from depletion of ATP (as demonstrated by in vivo 
NMR) and damage from free radical generation. It is to 
be noted that dosage values will also vary with the 
condition of the patient being treated. It is to be further 
understood that for any particular subject, specific dos 
age regimens should be adjusted over time according to 
the individual need and the professional judgment of the 
person administering or supervising the administration 
of the compositions, and that the concentration ranges 
set forth herein are exemplary only and are not intended 
to limit the scope or practice of the claimed composi 
tion. 
A preferred mode of administration of the active 
compound is in a form for oral delivery. Oral composi 
tions will generally include an inert diluent or an edible 
carrier. Preferred pharmaceutical carriers for intrave 
nous administration are saline or phosphate buffered 
saline at physiological pH. Since PBN degrades at pH 
less than approximately 3 to 4, it is preferred to adminis 
ter the PBN at a pH of 4 or higher, or in combination 
with food or a buffering agent. For oral delivery, the 
PBN may be enclosed in capsules, compressed into 
tablets, microencapsulated, entrapped in liposomes, in 
solution or suspension, alone or in combination with a 
substrate immobilizing material such as starch or poorly 
absorbable salts such as immodium. Pharmaceutically 
compatible binding agents, and/or adjuvant materials 
can be included as part of the composition. The tablets 
or, capsules may contain, for example, any of the fol 
lowing ingredients, or compounds of a similar nature: a 
binder such as microcrystalline cellulose, gum traga 
canth or gelatin; an excipient such as starch or lactose, 
a disintegrating agent such as alginic acid, Primogel ®, 
or corn starch; a lubricant such as magnesium stearate 
or Sterotes; a glidant such as colloidal silicon dioxide; a 
sweetening agent such as sucrose or saccharin; or a 
?avoring agent such as peppermint, methyl salicylate, 
or orange flavoring. When the dosage unit form is a 
capsule, it can contain, in addition to material of the 
above type, a liquid carrier such as a fatty oil. In addi 
tion, dosage unit forms can contain various other mate 
rials which modify'the physical form of the dosage unit, 
5,036,097 
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for example, coatings of sugar, shellac, or other enteric 
agents. 
The present invention will be further understood 
with reference to the following non-limiting examples 
demonstrating methods for determining effectiveness of 5 
PBN administration for treatment or prevention and/or 
reversal of damage from NSAIDS. 
EXAMPLE 1: COMPARISON OF 
PIROXICAM-INDUCED ULCER WITH 
CONTROL. 
The following materials and methods were used in 
examples 1 and 2. 
Animal Experiments. 
Male Sprague-Dawley rats (Charles River, Wilming 
ton, Mass.) weighing 300-325 g were housed individu 
ally in wire bottomed cages to prevent ingestion of hair 
and feces. Animals were maintained without food for 48 
hours and without water for 24 hours prior to each 
experiment. Piroxicam or aspirin and other NSAIDS 
were suspended in a vehicle of 1% carboxymethylcellu 
lose, 0.1% Tween 80 and 0.15 M HCl, and administered 
in a volume of 1 ml on the morning of study by oral 
gavage using an 18 gauge curved blunt needle (Popper 
and Sons, New Hyde Park, N.Y.). One ml of vehicle 
alone was administered for control experiments. HCl 
was added to the vehicle to insure an acid environment 
in the stomach in all studies. Preliminary experiments 
showed that 23 mg/kg piroxicam consistently produced 
15 
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30 
ulceration, and this dose was used in all subsequent - 
studies. Four hours after the administration of NSAID 
or vehicle, rats were euthanized with sodium pentobar 
bital (100 mg/kg IP), and the surface area of ulceration 
per stomach was quantitated using morphometric tech 
niques. Stomachs were removed, the lumen was ex 
posed by an incision along the radius of greater curva 
ture, and the stomach was washed in phosphate buff 
ered saline. The luminal surface was laid out on a flat 
surface with gross folds removed by gentle distension. 
The percentage of surface involved with submucosal 
hemorrhage was then determined by point counting, as 
described by Weibel, E. R. Stereological Methods: 
Practical Methods for Biological Morphometry. Aca 
demic Press, New York 1980. This was done by tabula 
tion of the percentage of points over ulcerations using a 
point counting eyepiece graticle (16x16 points in a 
square format). At the 12X magni?cation used on the 
Wild dissecting microscope (Wild-Heerbrugg, Basel, 
Switzerland), the graticle covered a 1 cm2 area of the 
surface. Four to live non-overlapping sampling sites 
were taken to fully cover the exposed surface. To deter 
mine the total luminal surface area, the outline of the 
outer boundary of the stomach was traced using a trans 
parent acetate sheet, and the area was determined from 
planimetry. The surface area of ulcerated regions per 
stomach was then determined by multiplying the sur 
face density of ulceration regions by the luminal surface 
area of the stomach. 
MEASUREMENT OF LIPID PEROXIDATION IN 
STOMACHS. 
Lipid peroxidation is studied in piroxicam-and vehi 
cle-treated rat stomachs by measuring thiobarbituric 
acid (TBA) reactivity of gastric punch biopsies by the 
method of Buege and Aust Buege, J. A., Aust, S. D. 
Methods Enzymol 51:302-310 (1978). Four hours after 
piroxicam or vehicle, stomachs are opened along the 
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radius of greater curvature, washed with ice cold nor 
mal saline, and spread along a ?at surface with lumens 
exposed. Five punch biopsies from mucosal through 
serosal surfaces are taken from each stomach using a 3 
mm diameter skin biopsy punch. Biopsies are taken over 
ulcers in piroxicam treated stomachs and randomly 
over gastric rugae (where ulcers occur) in vehicle con 
trol stomachs. Biopsies from each stomach are com 
bined, homogenized on ice in 1 ml of cold 1.15% KCl, 
and mixed with 2 ml of TBA reagent (0.375% thiobarbi 
turic acid and 15% trichloroacetic acid in 0.25 HCl, to 
which 0.01% butylated hydroxytoluene is added just 
prior to use). After incubation at 100° C. for 15 minutes, 
the mixture is cooled and centrifuged at 1,500 g for 10 
min. The absorbance of the supernatant is measured at 
532 nm, and results expressed as A532 per stomach. 
MEASUREMENT OF GLUTATHIONE IN 
GASTRIC MUCOSA. 
Gastric mucosal glutathione is measured in pirox 
icam-and vehicle-treated rat stomachs. Four hours after 
piroxicam or vehicle, stomachs are opened, washed 
with ice cold saline, and spread along a flat surface with 
lumens exposed. The gastric mucosa is then removed by 
scraping with a surgical blade. The mucosa is homoge 
nized on ice in 1 ml of 1.15% KCl. Two aliquots of 250 
pl are snap frozen in liquid nitrogen and stored at -—70° 
C. for later determination of total glutathione by the 
method of Anderson, M. E. Methods Enzymol 
113:548-555 (1985) and protein by a modi?cation of the 
Lowry method, described by Bennett, J. P. Techniques 
Lipid Membrane Biochem. B408:1—22 (1982), using 
bovine serum albumin as a standard. Results are ex 
pressed as nmole/mg protein. To measure oxidized 
glutathione (GSSG), the remaining 500 pl is mixed with 
an equal volume of N-ethylmaleimide (NEM) in water 
(10 mM final concentration of NEM), snap frozen and 
stored at —70° C. After thawing for analysis, this mix 
ture is passed over a C-18 Sep-Pak column (Waters 
Associates, Milford, Mass.) and washed with 1 ml phos 
phate buffer (pH 7.5). This technique for removing 
excess NEM has been previously shown to result in 
>90% recovery of GSSG. GSSG is then assayed by 
the method used above to determine total glutathione. 
MEASUREMENT OF GASTRIC XANTHINE 
OXIDASE ACTIVITY. 
Xanthine dehydrogenase (XDH) and oxidase (X0) 
activities are measured in whole stomach from pirox 
icam-treated and vehicle-treated rats, using methods 
reported by Parks, et. al. Am. J. Pathol. 254 (Gastroint 
est Liver Physiol 17): G768-G774 (1988). The artifac 
tual conversion of XDH to X0 is minimized by quickly 
removing stomachs from rats that were anesthetized 
with 50 mg/kg sodium pentobarbital and still breathing 
spontaneously. After gastrectomy, the rats are euth 
anized by cutting the abdominal aorta. Stomachs are 
quickly rinsed in an ice cold homogenizing buffer con 
sisting of 50 mM potassium‘ phosphate buffer, pH 7.0, 
containing 10 mM dithiothreitol (DTT), 1 mM phenyl 
methylsulfonyl ?uoride (PMSF) and 0.1 mM EDTA. 
The stomach is then immediately immersed in liquid 
nitrogen and ground to a fine powder under liquid ni 
trogen using a mortar and pestle. About 0.5 g of frozen 
powder is added to 5 ml of homogenizing buffer and 
centrifuged 40,000 g for 30 min. The supernatant is 
decanted and microfuged for an additional 10 min. Su 
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pematants are not stored but assayed less than 2 hours 
after collection to prevent loss of activity. I 
The spectrophotometric assay used is based on pro 
duction of uric acid at 295 nm (lambda295=1.l z 
104M-lcm—l). To increase reaction rates activity was 
measured at 30 rather than 25° C. One ml reaction mix 
tures contained 500 pl sample, 50 p.M xanthine and 100 
pM EDTA in 50 mM potassium phosphate buffer, pH 
7.8. X0 is assayed in the absence in NAD+, while 
XDH+XO activity is measured in the presence of 500 
uM NAD+. Enzyme activities are reported as interna 
tional units (1 umol of urate formed per min.). The 
extent of XDH conversion (% X0) is calculated from 
X0 activity divided by XDH+XO activity. 
Studies of Mitochondrial Respiration. 
Rat liver mitochondria are prepared using the 
method of Lai and Clark Methods Enzymol 55:51-60 
(1979). The livers are excised rapidly into ice cold isola 
tion medium containing 0.25M sucrose, 10 mM tris(hy 
droxymethyl)aminomethane (Tris), 0.25% bovine 
serum albumin (fatty acid free), and 0.5 mM potassium 
EDTA, pH 7.4. The tissue is minced and rinsed three 
times in cold isolation medium. The minced tissue is 
I placed in a Dounce homogenizer with 20 ml cold isola 
tion medium, gently homogenized, and diluted with an 
additional 10 ml of isolation medium. The homogenate 
is centrifuged at 2,000 g for 3 min., and the resulting 
supernatant recentrifuged at 12,500 g for 8 min. The 
crude mitochondrial pellet is suspended in 0.12M man 
nitol-0.03M sucrose medium containing 3% Ficoll, 
gently layered onto 20 ml of 6% Ficoll (0.25M man 
nitol-0.06M sucrose), and centrifuged at 11,500 g for 30 
min. The resulting mitochondrial pellet is resuspended 
in the isolation medium and recentrifuged for 10 min. at 
12,500 g. The final pellet is brought to a concentration 
of 10 to 15 mg of mitochondrial protein per ml with 
isolation medium. Mitochondrial protein is determined 
by the Biuret reaction described by Gornall, A. G., et 
al. Biol Chem 177:751-766 (1949), using bovine serum 
albumin as a standard. Mitochondrial respiration is mea 
sured polarographically in a magnetically stirred cham 
bet at 25° C., using a Clark microelectrode (Diamond 
Electro-tech, Ann Arbor, Mich). The incubation me 
dium contains the following (in mM): 5K+, 226 manni 
tol, 75 sucrose, 5 Tris-phosphate, l0 Tris-Cl, and 0.05 
EDTA at pH 7.4. State 4 respiratory rates are deter 
mined using both NADH-linked (2.5 mM malate+2 
mM glutamate) and FADHz-lined (10 mM succinate) 
substrates, with 5 mM KCl at pH 7.0. State 3 respiration 
rates are measured after stimulation with 1.5 mM ADP. 
Respiratory control ratios are determined as the ratio of 
State 3 to State 4 respiration after incubation with 0, 50, 
100 and 200 pM piroxicam. 
Studies of Microsomal Lipid Peroxidation. 
Microsomes are isolated from rat livers by modi?ca 
tion of the method of Fleisher and Kervina, Methods 
Enzymol 31:7-41 (1974). Rats are euthanized by C02 
narcosis. The livers are excised rapidly into cold isola 
tion medium containing 0.1M sodium phosphate and 2 
mM EDTA, pH 7.4. The tissue is minced and homoge 
nized in 3 ml isolation medium per gram of tissue using 
a Potter-Elvehjam homogenizer. The homogenate is 
centrifuged at 17,800 g for 20 min., and the pellet dis 
carded. The supernatant is recentrifuged at 100,000 g 
for 60 min. The resulting pellet is. resuspended in isola 
tion buffer and recentrifuged at 100,000 g for 40 min. 
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The ?nal pellet is resuspended in storage buffer contain 
ing 100 mM potassium phosphate, 20% glycerol, 1 mM 
EDTA, 1 mM DTT and 20 uM butylated hydroxytolu 
ene, pH 7.25. This suspension is frozen under liquid 
nitrogen and stored at —70° CL until use. Microsomal 
protein is determined by a modi?cation of the Lowry 
method of Anderson, M. E. Methods Enzymol 
113:548-555 (1985). The effect of 200 p.M piroxicam on 
microsomal lipid peroxidation is studied by incubating 1 
mg microsomal protein in 100 mM potassium phos 
phate, pH 7.25, on a shaking water bath at 37‘ CL for 90 
min., with and without the addition of 2 mM NADPH 
or 1 mM EDTA. Lipid peroxidation in the 1 ml reaction 
mixture is measured by mixing with 2 ml TBA reagent 
and assaying for thiobarbituric acid reactivity by the 
method of Buege and Aust. Values are expressed as the 
increase in absorbance at 532 nm (A532) per mg micro 
somal protein and represent the mean of three repli 
cates. 
Statistical Analysis. 
Differences in total luminal surface area in cmz, sur 
face area of ulcerated regions per stomach and bio 
chemical analyses between each treatment intervention 
and its corresponding untreated control group are com 
pared using the Mann-Whitney U Test, Dixon, W. J., 
Massey, F, J ., Jr. Introduction to statistical methods, 4th 
edition. (New York: McGraw Hill, 1983). The effect of 
treatment interventions on NSAID-induced ulceration 
are displayed graphically as % of control ulceration, 
determined by summing the ratios of cm2 ulceration in 
each treatment stomach to the mean cm2 ulceration of 
respective untreated NSAID control stomachs, and 
multiplying +100. In vitro studies are compared using 
the Student’s unpaired T-test, Dixon, W. .I., Massey, F. 
J., Jr. Introduction to statistical methods, 4th edition. 
(New York: McGraw Hill, 1983). Values are expressed 
as mean-.LSEM. Signi?cance is assumed when P<0.05. 
Reagents and Pharmaceuticals. 
Phenyl N-tert-butyl nitrone is obtained from Aldrich 
Chemicals, Milwaukee, Wis. All other chemicals and 
pharmaceuticals are from Sigma Chemical. Piroxicam 
caused profound gastric ulceration. FIG. 1 shows that 
piroxicam-induced ulcers usually occurred only on the 
ridges of gastric rugae and spread linearly along these 
ridges, without involvement of the remaining gastric 
surface area. In the absence of an intervention, a mean 
of 0.215 cm2 ulceration was present in piroxicam-treated 
control stomachs. However, the degree of ulceration in 
this highly stress-dependent model was variable, rang 
ing among experiments from 0.03 10.009 to 
0706:0104 cmz. For this reason, each treatment inter 
vention was compared to its own group of control rats 
that were fasted simultaneously and treated with pirox 
icam at the same time. 
EXAMPLE 2: SUPPRESSION OF 
PIROXICAM-INDUCED ULCERS BY FREE 
RADICAL SCAVENGERS. 
Piroxicam was selected as a model NSAID because it 
is highly ulcerogenic in rats and mice, yet is a relative 
weak reversible inhibitor of prostaglandin synthesis. 
The spin trap phenylbutyl nitrone (PBN) was used to 
explore the role of free radicals and oxidative events 
mediated by xanthine oxidase- and iron-mediated oxi 
dant injury in the pathogenesis of piroxicam-induced 
gastric ulcers. In each experiment, the surface area of 
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gastric ulceration produced by piroxicam in 15 treated 
rats was compared to that in 15 rats of the same age and 
size that were fasted simultaneously but which received 
no intervention. Phenylbutyl nitrone (30 mg/kg) was 
given orally in water 1 hour before piroxicam and also 
added to vehicle when piroxicam was administered. 
When intervention were given with piroxicam, the pH 
of the ?nal mixture was adjusted if necessary to equal 
that of piroxicam and vehicle alone. 
To generalize the ?ndings relative to piroxicam to 
other NSAIDS, the effect of PBN, administered as 
above, can be compared with the effect on gastric ulcer 
ation from aspirin (200 mg/kg), di?unisal (125 mg/kg), 
naproxen (150 mg/kg) and ibuprofen (230 mg/kg). 
Piroxicam-induced ulcers were markedly reduced in 
rats treated with free radical scavengers, as shown in 
FIG. 2, suggesting that generation of reactive oxygen 
species is an important mechanism in the pathogensis of 
piroxicam-induced ulcers. In ulcerations/unit area, 
piroxicam only produced 0229:0145 ulcerations/ unit 
area, and piroxicam plus PBN produced 0.077:0.l04 
ulcerations/unit area, statistically signi?cant at 
p<0.0052. In contrast, ascorbate, a reducing substance 
that is well-recognized to facilitate iron-dependent gen 
eration of reactive oxygen species, increased ulceration 
by over 600% compared to control stomachs treated 
with piroxicam alone (O.l94:0.039 cm2 ulceration in 
ascorbate-treated stomachs vs 0031:0009 cm2 in 
stomachs receiving piroxicam alone, P<0.00l). In sup 
port of an oxidant mechanism as the pathogenesis of 
ulcers from piroxicam, thiobarbituric acid reactivity 
was signi?cantly increased in gastric biopsies from 
piroxicam treated rats compared to rats treated with 
vehicle alone (A532=0.lO4:0.0l0 for piroxicam vs 
0.075:0.004 for vehicle treated stomachs, P<0.05). 
Piroxicam also decreased total glutathione in gastric 
mucosa (0.33:0.03 nmoles/mg protein) compared to 
vehicle alone (0.042:0.07 nmoles/mg protein) and 
increased the fraction of GSSG (8.9 :0.9 for piroxicam 
vs 6.4 0.7% for vehicle), although these differences 
failed to achieve statistical signi?cance. 
Xanthine oxidase activity was readily identi?ed in 
whole stomach. Piroxicam treated stomachs had 
30.5:l.6 mU/g of total XHD+XO activity, of which 
45 :3% was XO. Vehicle treated control stomachs had 
31.6:2.45 mU/g X. Piroxicam increases the rate of 
35 
mitochondrial oxygen uptake in the absence of ADP ' 
(State 4) and that normal stimulation of respiration by 
ADP (State 3) is lost in the presence of piroxicam. This 
inhibition of respiratory control by piroxicam was dem 
onstrated for both FADHg-linked and NADH-linked 
substrates. However, piroxicam did not increase gener 
ation of OZ-by mitochondrial respiration. Piroxicam had 
no effect on NADPH-dependent microsomal lipid 
peroxidation. > 
Aspirin (0972:0318 cmz), diflunisal (0597:0103 
cmz), naproxen (0370:0056 cm2) and ibuprofen 
50 
(0644:0110 cmZ) also caused severe gastric ulcer-, 
ation. In summary, ulceration from piroxicam was 
markedly inhibited by the spin-trap PBN. 
EXAMPLE 3: NON-TOXICITY OF PBN AND 
BIOAVAILABILITY. ' 
Previous studies on mutagenicity using standard tech 
niques have demonstrated that PBN and analogs 
thereof are not mutagenic. In addition, in vitro cytotox 
icity tests using human lymphocytes have indicated that 
65 
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PBN in concentrations of up to at least 100 pjmolar have 
no cytotoxic effect. 
In vivo toxicity tests have indicated the following. 
Acute doses of PBN in doses up to 3 g/kg in rodents 
have no adverse effects. An LD50 has yet to be deter 
mined because of the lack of toxicity. Acute i.v. doses of 
PBN ranging from 10 to 300 mg/kg body weight (in 
jected within 60 seconds) have no acute toxic effects in 
gerbils. Continuous i.v. administration of PBN at a dose 
of 50 mg/kg/hr for a total of 48 hr has no adverse effect 
on gerbils. 
An estimate of the bioavailability of PBN demon 
strates that it is widely available throughout the body 
and is able to cross all of the barriers to distribution, 
including the blood brain barrier (the brain shows 80% 
of the plasma concentration). Limited pharmokinetic 
studies indicate that the plasma half-life in the rat is 
three to four hours. 
Modi?cations and variations of the present invention, 
compositions containing PBN and derivatives thereof, 
and methods using the compositions for the treatment 
or prevention of gastric ulceration resulting from inges 
tion of non-steroidal anti-inflammatories, will be obvi 
ous to those skilled in the art from the foregoing de 
tailed description. Such modi?cations and variations are 
intended to come within the scope of the following 
claims. 
We claim: 
1. A method for in vivo treatment or prevention of 
gastric ulceration from ingestion of non-steroidal anti 
in?ammatories comprising: 
administering to a patient in need of such treatment 
a-phenyl t-butyl nitrone and derivatives thereof 
having spin-trapping activity and preventing ATP 
depletion in vivo in tissue having the formula; 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
O 0 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
ingredient a-phenyl t-butyl nitrone. 
of gastric ulceration comprising: 
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wherein W is 
O 
ff 15 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; and 
a pharmaceutically acceptable carrier for oral admin- 20 
istration to a patient, in a dosage effective to treat 
or prevent gastric ulceration from ingestion of 
nonsteroidal antiinflammatory compounds. 
, 2. The method of claim 1 wherein the phenyl butyl 
nitrone derivatives are selected from the group consist 
ing of hydroxy PBNs, PBN esters, acetoxy PBNs, alkyl 
PBNs, alkoxyl PBNs, phenyl PBNs. 
25 
3. The method of claim 1 wherein the PBN derivative 
is functionalized to release in vivo a compound selected 
from the group consisting of 2-, 3-, and 4-hydroxyphe 
nyl t-butyl nitrone; 2-, 3-, and 4-hydroxyphenyl t-butyl 
nitrone; 2-, 3-, and 4-carboxyphenyl t-butyl nitrone; and 
2-, 3-, and 4-aminophenyl t-butyl nitrone._ 
4. The method of claim 1 comprising as the active 35 
5. The method of claim 1 wherein the PBN and deriv 
atives thereof is in a pharmaceutical carrier delivering 
an effective dosage to a patient to treat or prevent gas 
tric ulceration from simultaneous ingestion of nonsteroi 
dal antiinflammatory compounds. 
6. The method of claim 1 wherein the PBN and deriv 
atives thereof is in a pharmaceutical carrier delivering 
an effective dosage to a patient to treat or prevent gas 
tric ulceration from subsequent ingestion of non-steroi 
dal anti-inflammatoriy compounds. 
45 
7. The method of claim 6 wherein the non-steroidal 
anti-in?ammatory is selected from the group consisting 
of aspirin, acetaminophen, ibuprofen, piroxicam, na 
proxen, flufenamic and methanamic acid and related 
nonsteroidal antiinflammatory compounds. 
50 
8. The method of claim 1 wherein the PBN and deriv 
atives thereof is provided in a dosage of between 3 and 
300 mg PBN/kg body weight. 
9. The method of claim 8 wherein the PBN and 55 
derivaties thereof is provided in a dosage of between 10 
and 30 mg/kg body weight. 
10. The method of claim 1 wherein the PBN and 
derivatives thereof is provided in combination with a 
pharmaceutical carrier selected from the group consist 
ing of microcapsules, liposomes, immobilizing sub 
strates, salts that are poorly absorbed through the gas 
trointestinal lining, oils, and buffering agents. 
11. A composition for in vivo treatment or prevention 
65 
a-phenyl t-butyl nitrone and derivatives thereof hav 
ing spintrapping activity and preventing ATP de 
pletion in vivo in tissue having the formula; 
14 
H O“ 
C=N+ 
\ 
X Y 
wherein: 
X is phenyl or 
(OR)n 
wherein R is H, 
O 0 
ll / 
Z—C—, or Z; or -'CH=N , \ 
Y 
and n is a whole integer from 1 to 5; or 
Y is a tert-butyl group that can be hydroxylated or 
acetylated on one or more positions; phenyl; or 
OW 
wherein W is 
o o 
I! 
or Z; and 
Z is a C1 to C5 straight or branched alkyl group; and 
a pharmaceutically acceptable carrier for oral admin 
istration to a patient, wherein the a-phenyl t-butyl 
nitrone and derivatives thereof is in a dosage effec 
tive to prevent or treat gastric ulceration by non 
steroidal antiinflammatory compounds wherein the 
PBN and derivatives thereof is in combination with 
a non-steroidal anti-in?ammatory, said agents 
being present in effective amounts. 
12. The composition of claim 11 wherein the phenyl 
butyl nitrone derivatives are selected from the group 
consisting of hydroxy PBNs, PBN esters, acetoxy 
PBNs, alkyl PBNs, alkoxyl PBNs, phenyl PBNs. 
13. The composition of claim 2 wherein the PBN 
derivative is functionalized to release in vivo a com 
pound selected from the group consisting of 2-, 3-, and 
4-hydroxyphenyl t-butyl nitrone; 2-, 3-, and 4-hydrox 
yphenyl t-butyl nitrone; 2-, 3-, and 4-carboxyphenyl 
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t-butyl nitrone; and 2-, 3-, and 4-aminophenyl t-butyl 
nitrone. 
14. The composition of claim 11 comprising as the 
active ingredient a-phenyl t-butyl nitrone. 
15. The composition of claim 11 wherein the PBN 
and derivatives thereof is in a pharmaceutical carrier . 
delivering an effective dosage to a patient to prevent 
1O 
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injury from simultaneous ingestion of a non-steroidal 
anti-in?ammatory compound. 
16. The composition of claim 11 wherein the non 
steroidal anti-in?ammatory is selected from the group 
consisting of aspirin, acetaminophen, ibuprofen, pirox 
'icam, naproxen, ?ufenamic and methanamic acid and 
related nonsteroidal antiinflammatory compounds. 
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